Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Feldman

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Journal of the American Academy of Child and Adolescent Psychiatry|April 22, 2005
Atomoxetine and tics in ADHDPeter D Feldman, Dustin D Ruff, Albert J Allen
Comprehensive Psychiatry|February 12, 2011
Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophreniaHong Liu-Seifert, Olawale O Osuntokun, Peter D Feldman
Journal of the American Academy of Child and Adolescent Psychiatry|April 24, 2007
Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetineLaurence L Greenhill, Jeffrey H Newcorn, Haitao Gao, et al.
Patient Preference and Adherence|November 5, 2010
Patient perspectives on antipsychotic treatments and their association with clinical outcomesHong Liu-Seifert, Olawale O Osuntokun, Jenna L Godfrey, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines|March 25, 2009
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placeboJan K Buitelaar, Timothy E Wilens, Shuyu Zhang, et al.
Journal of Child and Adolescent Psychopharmacology|May 21, 2013
A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regionsYoko Tanaka, Luis A Rohde, Ling Jin, et al.
Human Psychopharmacology|August 9, 2011
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapineDavid P McDonnell, Ludmila A Kryzhanovskaya, Fangyi Zhao, et al.
Clinical Neuropharmacology|October 22, 2005
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instrumentsKelvin L Chou, Susan Messing, David Oakes, et al.
International Journal of General Medicine|May 23, 2012
Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisonsHaya Ascher-Svanum, William S Montgomery, David P McDonnell, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 25, 2009
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial studyRichard C Mohs, Thomas M Shiovitz, Pierre N Tariot, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Journal of the American Academy of Child and Adolescent Psychiatry|April 22, 2005
Atomoxetine and tics in ADHDPeter D Feldman, Dustin D Ruff, Albert J Allen
Comprehensive Psychiatry|February 12, 2011
Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophreniaHong Liu-Seifert, Olawale O Osuntokun, Peter D Feldman
Journal of the American Academy of Child and Adolescent Psychiatry|April 24, 2007
Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetineLaurence L Greenhill, Jeffrey H Newcorn, Haitao Gao, et al.
Patient Preference and Adherence|November 5, 2010
Patient perspectives on antipsychotic treatments and their association with clinical outcomesHong Liu-Seifert, Olawale O Osuntokun, Jenna L Godfrey, et al.
Journal of Child Psychology and Psychiatry, and Allied Disciplines|March 25, 2009
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placeboJan K Buitelaar, Timothy E Wilens, Shuyu Zhang, et al.
Journal of Child and Adolescent Psychopharmacology|May 21, 2013
A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regionsYoko Tanaka, Luis A Rohde, Ling Jin, et al.
Human Psychopharmacology|August 9, 2011
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapineDavid P McDonnell, Ludmila A Kryzhanovskaya, Fangyi Zhao, et al.
Clinical Neuropharmacology|October 22, 2005
Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instrumentsKelvin L Chou, Susan Messing, David Oakes, et al.
International Journal of General Medicine|May 23, 2012
Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisonsHaya Ascher-Svanum, William S Montgomery, David P McDonnell, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 25, 2009
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial studyRichard C Mohs, Thomas M Shiovitz, Pierre N Tariot, et al.
Pageof 3